Elanco Animal Health Inc (NYSE: ELAN) has a higher price-to-earnings ratio of 15.96x compared to its average ratio. ELAN has 36-month beta value of 1.56. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ELAN is 491.95M, and currently, short sellers hold a 5.04% ratio of that float. The average trading volume of ELAN on May 12, 2025 was 5.38M shares.
ELAN) stock’s latest price update
The stock price of Elanco Animal Health Inc (NYSE: ELAN) has plunged by -2.61 when compared to previous closing price of 12.28, but the company has seen a 22.67% gain in its stock price over the last five trading sessions. https://thefly.com reported 2025-05-07 that Leerink analyst Daniel Clark raised the firm’s price target on Elanco to $11 from $9.50 and keeps a Market Perform rating on the shares. The firm says the company’s quarter was solid, and its exposure to tariffs was less than many feared. These two factors vs. bearish positioning are likely driving a bit of a squeeze in shares today. The updated guide appears prudent to Leerink, factoring in potential downside from pharmaceutical tariffs as well as the full impact of China tariffs at current rates, net of mitigation efforts. Ultimately, Elanco continues to be a second half of 2025 and 2026 growth story, the firm argues. 07 May
ELAN’s Market Performance
ELAN’s stock has risen by 22.67% in the past week, with a monthly rise of 27.51% and a quarterly rise of 3.82%. The volatility ratio for the week is 5.58% while the volatility levels for the last 30 days are 4.82% for Elanco Animal Health Inc The simple moving average for the past 20 days is 25.29% for ELAN’s stock, with a -2.69% simple moving average for the past 200 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with UBS repeating the rating for ELAN by listing it as a “Buy.” The predicted price for ELAN in the upcoming period, according to UBS is $18 based on the research report published on December 09, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $14. The rating they have provided for ELAN stocks is “Market Perform” according to the report published on December 02nd, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to ELAN, setting the target price at $15 in the report published on September 19th of the previous year.
ELAN Trading at 19.31% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.38% of loss for the given period.
Volatility was left at 4.82%, however, over the last 30 days, the volatility rate increased by 5.58%, as shares surge +37.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.52% upper at present.
During the last 5 trading sessions, ELAN rose by +22.67%, which changed the moving average for the period of 200-days by -9.80% in comparison to the 20-day moving average, which settled at $9.55. In addition, Elanco Animal Health Inc saw -1.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELAN starting from Kurzius Lawrence Erik, who purchase 10,000 shares at the price of $10.90 back on Mar 07 ’25. After this action, Kurzius Lawrence Erik now owns 101,459 shares of Elanco Animal Health Inc, valued at $109,000 using the latest closing price.
Kurzius Lawrence Erik, the Director of Elanco Animal Health Inc, purchase 10,000 shares at $10.20 during a trade that took place back on Mar 11 ’25, which means that Kurzius Lawrence Erik is holding 111,459 shares at $102,000 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.46 for the gross margin
The net margin for Elanco Animal Health Inc stands at 0.08. The total capital return value is set at 0.02. Equity return is now at value 6.01, with 2.77 for asset returns.
Based on Elanco Animal Health Inc (ELAN), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is 1.07.
Currently, EBITDA for the company is 1.49 billion with net debt to EBITDA at 5.8. When we switch over and look at the enterprise to sales, we see a ratio of 2.21. The receivables turnover for the company is 5.01for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.71.
Conclusion
To put it simply, Elanco Animal Health Inc (ELAN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
